Skip Nav Destination
Issues
15 April 2024
-
Cover Image
Cover Image
The multispectral image of lung squamous cell carcinoma shows activation and regulatory T cells. Pancytokeratin (cyan), CD3 (red), CD8 (pink), granzyme B (orange), CD45RO (yellow), and FOXP3 (green) are shown. The image was generated using a Vectra/Polaris 3.0.3 scanner and InForm software 2.4.8 at 20X. For details, see the article by Parra and colleagues on page 1655 of this issue. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
Reviews
Facts and Hopes on Biomarkers for Successful Early Clinical Immunotherapy Trials: Innovative Patient Enrichment Strategies
Michael A. Cannarile; Vaios Karanikas; Bernhard Reis; Christoph Mancao; Eleni Lagkadinou; Dominik Rüttinger; Natascha Rieder; Franclim R. Ribeiro; Henry Kao; Sebastian Dziadek; Bruno Gomes
Clinical Trials: Targeted Therapy
Clinical Activity of TGF-β Inhibitor Vactosertib in Combination with Imatinib in Desmoid Tumors: A Multicenter Phase Ib/II Study
Jin-Hee Ahn; Jeeyun Lee; Changhee Park; Seung-Hoon Beom; Seung Hyun Kim; Young Han Lee; Kum-Hee Yun; Jeung Eun Kim; Wooyeol Baek; Yoon Dae Han; Sang Kyum Kim; Hyang Joo Ryu; Inkyung Jung; JooHee Lee; Hong In Yoon; Hyo Song Kim
Safety Profile and Adverse Event Management for Futibatinib, An Irreversible FGFR1–4 Inhibitor: Pooled Safety Analysis of 469 Patients
Funda Meric-Bernstam; Antoine Hollebecque; Junji Furuse; Do-Youn Oh; John A. Bridgewater; Masashi Shimura; Bailey Anderson; Nanae Hangai; Volker Wacheck; Lipika Goyal
Nicotinamide in Combination with EGFR-TKIs for the Treatment of Stage IV Lung Adenocarcinoma with EGFR Mutations: A Randomized Double-Blind (Phase IIb) Trial
Hyung-Joo Oh; Suk-Chul Bae; In-Jae Oh; Cheol-Kyu Park; Kyoung-Mi Jung; Da-Mi Kim; Jung-Won Lee; Chang Kyun Kang; Il Yeong Park; Young-Chul Kim
Clinical Trials: Immunotherapy
A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer
Tanya Dorff; Lisa G. Horvath; Karen Autio; Alice Bernard-Tessier; Matthew B. Rettig; Jean-Pascal Machiels; Mehmet A. Bilen; Martijn P. Lolkema; Nabil Adra; Sylvie Rottey; Richard Greil; Nobuaki Matsubara; Daniel S.W. Tan; Alvin Wong; Hiroji Uemura; Charlotte Lemech; Johannes Meran; Youfei Yu; Mukul Minocha; Mason McComb; Hweixian Leong Penny; Vinita Gupta; Xuguang Hu; Gabor Jurida; Hosein Kouros-Mehr; Margit M. Janát-Amsbury; Tobias Eggert; Ben Tran
Cadonilimab Combined with Chemotherapy with or without Bevacizumab as First-Line Treatment in Recurrent or Metastatic Cervical Cancer (COMPASSION-13): A Phase 2 Study
Hanmei Lou; Hongbing Cai; Xin Huang; Guiling Li; Li Wang; Fei Liu; Wenjing Qin; Ting Liu; Wei Liu; Zhongmin Maxwell Wang; Baiyong Li; Yu Xia; Jing Wang
Precision Medicine and Imaging
Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor–Positive Postmenopausal Breast Cancer Patients in the TEAM Trial
John M.S. Bartlett; Keying Xu; Jenna Wong; Gregory Pond; Yi Zhang; Melanie Spears; Ranelle Salunga; Elizabeth Mallon; Karen J. Taylor; Annette Hasenburg; Christos Markopoulos; Luc Dirix; Cornelis J.H. van de Velde; Daniel Rea; Catherine A. Schnabel; Kai Treuner; Jane Bayani
ERBB3 Overexpression is Enriched in Diverse Patient Populations with Castration-sensitive Prostate Cancer and is Associated with a Unique AR Activity Signature
Jordan E. Vellky; Brenna J. Kirkpatrick; Lisa C. Gutgesell; Mathias Morales; Ryan M. Brown; Yaqi Wu; Mark Maienschein-Cline; Lucia D. Notardonato; Michael S. Weinfeld; Ryan H. Nguyen; Eileen Brister; Maria Sverdlov; Li Liu; Ziqiao Xu; Steven Kregel; Larisa Nonn; Donald J. Vander Griend; Natalie M. Reizine
Translational Cancer Mechanisms and Therapy
Development of Chromosome 1q+ Specific Treatment for Highest Risk Pediatric Posterior Fossa Ependymoma
Andrea M. Griesinger; Annaliese J. Calzadilla; Enrique Grimaldo; Andrew M. Donson; Vladimir Amani; Angela M. Pierce; Jenna Steiner; Soudabeh Kargar; Natalie J. Serkova; Kelsey C. Bertrand; Karen D. Wright; Rajeev Vibhakar; Todd Hankinson; Michael Handler; Holly B. Lindsay; Nicholas K. Foreman; Kathleen Dorris
Cooperative Armoring of CAR and TCR T Cells by T Cell–Restricted IL15 and IL21 Universally Enhances Solid Tumor Efficacy
Rosa Nguyen; Ekaterina Doubrovina; Charlotte M. Mousset; Benjamin Y. Jin; Reona Okada; Xiyuan Zhang; Arina Clavel; Jeyshka M. Reyes-Gonzalez; Vadim Dyomin; Louis Diaz; Ling Zhang; Shahroze Abbas; Ming Sun; Chao-Ming Hsieh; Mitchell Ho; Jack F. Shern; James L. Gulley; Christian S. Hinrichs
A B7-H4–Targeting Antibody–Drug Conjugate Shows Antitumor Activity in PARPi and Platinum-Resistant Cancers with B7-H4 Expression
Sarah B. Gitto; Margaret Whicker; Gareth Davies; Sushil Kumar; Krista Kinneer; Haineng Xu; Arthur Lewis; Srinivas Mamidi; Sergey Medvedev; Hyoung Kim; Judith Anderton; E. Jessica Tang; Benjamin Ferman; Steven Coats; Robert W. Wilkinson; Eric Brown; Daniel J. Powell, Jr; Fiona Simpkins
Discovery of a Novel Potent EGFR Inhibitor Against EGFR Activating Mutations and On-Target Resistance in NSCLC
Eun Ji Lee; Seung Yeon Oh; You Won Lee; Ju Young Kim; Min-Je Kim; Tae Ho Kim; Jii Bum Lee; Min Hee Hong; Sun Min Lim; Anke Baum; Lydia Woelflingseder; Harald Engelhardt; Mark Petronczki; Flavio Solca; Mi Ran Yun; Byoung Chul Cho
CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors
Sophie Archer; Phillip M. Brailey; Minjung Song; Phillip D. Bartlett; Ines Figueiredo; Bora Gurel; Christina Guo; Verena Brucklacher-Waldert; H. Lorraine Thompson; Jude Akinwale; Samantha E. Boyle; Christine Rossant; Neil R. Birkett; Julia Pizzey; Mark Maginn; James Legg; Richard Williams; Colette M. Johnston; Philip Bland-Ward; Johann S. de Bono; Andrew J. Pierce
Paclitaxel and Carboplatin in Combination with Low-intensity Pulsed Ultrasound for Glioblastoma
Karl J. Habashy; Crismita Dmello; Li Chen; Victor A. Arrieta; Kwang-Soo Kim; Andrew Gould; Mark W. Youngblood; Guillaume Bouchoux; Kirsten B. Burdett; Hui Zhang; Michael Canney; Roger Stupp; Adam M. Sonabend
Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors
Solange Peters; Eric Angevin; Teresa Alonso-Gordoa; Kristoffer Rohrberg; Ignacio Melero; Begoña Mellado; Jose-Luis Perez-Gracia; Josep Tabernero; Celine Adessi; Christophe Boetsch; Carl Watson; Joseph Dal Porto; David Dejardin; Christopher Del Nagro; Valeria Nicolini; Stefan Evers; Christian Klein; Barbara Leutgeb; Pavel Pisa; Eva Rossmann; José Saro; Pablo Umana; Jehad Charo; Volker Teichgräber; Neeltje Steeghs
One CD4+TCR and One CD8+TCR Targeting Autochthonous Neoantigens Are Essential and Sufficient for Tumor Eradication
Steven P. Wolf; Vasiliki Anastasopoulou; Kimberley Drousch; Markus I. Diehl; Boris Engels; Poh Yin Yew; Kazuma Kiyotani; Yusuke Nakamura; Karin Schreiber; Hans Schreiber; Matthias Leisegang
Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial
Edwin Roger Parra; Jiexin Zhang; Dzifa Yawa Duose; Edgar Gonzalez-Kozlova; Mary W. Redman; Hong Chen; Ganiraju C. Manyam; Gayatri Kumar; Jianhua Zhang; Xingzhi Song; Rossana Lazcano; Mario L. Marques-Piubelli; Caddie Laberiano-Fernandez; Frank Rojas; Baili Zhang; Len Taing; Aashna Jhaveri; Jacob Geisberg; Jennifer Altreuter; Franziska Michor; James Provencher; Joyce Yu; Ethan Cerami; Radim Moravec; Kasthuri Kannan; Rajyalakshmi Luthra; Gheath Alatrash; Hsin-Hui Huang; Hui Xie; Manishkumar Patel; Kai Nie; Jocelyn Harris; Kimberly Argueta; James Lindsay; Roshni Biswas; Stephen Van Nostrand; Seunghee Kim-Schulze; Jhanelle E. Gray; Roy S. Herbst; Ignacio I. Wistuba; Scott Gettinger; Karen Kelly; Lyudmila Bazhenova; Sacha Gnjatic; J. Jack Lee; Jianjun Zhang; Cara Haymaker
RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer
Harshabad Singh; Pranshu Sahgal; Kevin Kapner; Steven M. Corsello; Hersh Gupta; Rahul Gujrathi; Yvonne Y. Li; Andrew D. Cherniack; Raquelle El Alam; Joseph Kerfoot; Elizabeth Andrews; Annette Lee; Chetan Nambiar; Alison M. Hannigan; Joshua Remland; Lauren Brais; Meghan E. Leahy; Douglas A. Rubinson; Benjamin L. Schlechter; Matthew Meyerson; Yanan Kuang; Cloud P. Paweletz; Jessica K. Lee; Julia C.F. Quintanilha; Andrew J. Aguirre; Kimberly J. Perez; Brandon M. Huffman; Humberto Rossi; Thomas A. Abrams; Sheheryar Kabraji; Livio Trusolino; Andrea Bertotti; Ewa T. Sicinska; Aparna R. Parikh; Brian M. Wolpin; Alexa B. Schrock; Marios Giannakis; Kimmie Ng; Jeffrey A. Meyerhardt; Jason L. Hornick; Nilay S. Sethi; James M. Cleary
A Real-world Toxicity Atlas Shows that Adverse Events of Combination Therapies Commonly Result in Additive Interactions
Asli Küçükosmanoglu; Silvia Scoarta; Megan Houweling; Nicoleta Spinu; Thomas Wijnands; Niek Geerdink; Carolien Meskers; Georgi K. Kanev; Bert Kiewiet; Mathilde Kouwenhoven; David Noske; Tom Wurdinger; Marianne Pouwer; Mark Wolff; Bart A. Westerman
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds
